Literature DB >> 8386982

DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide.

N Giocanti1, C Hennequin, J Balosso, M Mahler, V Favaudon.   

Abstract

The interactions between ionizing radiation and etoposide were probed using asynchronous growing V-79 fibroblasts. Synergistic cell kill was observed as gamma-rays were applied prior to or concomitantly with the drug. Three major determinants of enhanced cytotoxicity in combined treatment were identified. The kinetic analysis of radiation recovery bore evidence of two repair interaction mechanisms. First, rapidly repairable radiation-induced DNA damage was fixed into lethal lesions by etoposide, thus giving rise to marked supra-additive interaction under concomitant radiation-drug exposure. Second, cells arrested in G2 phase following radiation proved hypersensitive to the cytotoxic effect of etoposide. It is proposed that either topoisomerase II alpha is closely involved in some rapid DNA repair pathway operating during all phases of the cell cycle, and even further involved in DNA repair acting within the radiation-induced G2 block, or that the lesions induced by etoposide are able to impair these processes. The shoulder of the radiation survival curve was abolished as gamma-rays and drug were applied at 1-h intervals. This effect, corresponding to mode II additivity from isobologram determinations, appeared to be correlated with a differential sensitivity of the various phases of the cell cycle to drug and radiation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386982

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.

Authors:  Jeremy Lewin; Carleen Cullinane; Tim Akhurst; Kelly Waldeck; D Neil Watkins; Aparna Rao; Peter Eu; Linda Mileshkin; Rodney J Hicks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-16       Impact factor: 9.236

2.  Inhibition of topoisomerase IIα sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.

Authors:  Ekram M Saleh
Journal:  Tumour Biol       Date:  2015-06-17

3.  Radiosensitization by the novel DNA intercalating agent vosaroxin.

Authors:  Ira K Gordon; Christian Graves; Whoon J Kil; Tamalee Kramp; Philip Tofilon; Kevin Camphausen
Journal:  Radiat Oncol       Date:  2012-02-27       Impact factor: 3.481

4.  Implications of therapy-induced selective autophagy on tumor metabolism and survival.

Authors:  Luke R K Hughson; Vincent I Poon; Jaeline E Spowart; Julian J Lum
Journal:  Int J Cell Biol       Date:  2012-04-05

Review 5.  Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.

Authors:  John Conibear
Journal:  Br J Cancer       Date:  2020-12       Impact factor: 7.640

6.  Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02.

Authors:  Yungan Tao; Etienne Bardet; Dominique Rosine; Frédéric Rolland; Emmanuelle Bompas; Nicolas Daly-Schveitzer; Antoine Lusinchi; Jean Bourhis
Journal:  Radiat Oncol       Date:  2013-02-27       Impact factor: 3.481

7.  Repair of DNA strand breaks in a minichromosome in vivo: kinetics, modeling, and effects of inhibitors.

Authors:  Slawomir Kumala; Krzysztof Fujarewicz; Dheekollu Jayaraju; Joanna Rzeszowska-Wolny; Ronald Hancock
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

8.  Rapid polymerase chain reaction assay to detect variation in the extent of gene-specific damage between cisplatin- or VP-16-resistant and sensitive lung cancer cell lines.

Authors:  F Oshita; N Saijo
Journal:  Jpn J Cancer Res       Date:  1994-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.